Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

NCT07418190 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Follicular Lymphoma

Interventions

DRUG: tislelizumab + zanubrutinib + rituximab + lenalidomide

Sponsor

The First Affiliated Hospital with Nanjing Medical University